Current approaches for the treatment of multiple myeloma

被引:30
作者
Watanabe, Reiko [1 ]
Tokuhira, Michihide [1 ]
Kizaki, Masahiro [1 ]
机构
[1] Saitama Med Univ, Saitama Med Ctr, Div Hematol, Kawagoe, Saitama 3508550, Japan
基金
日本学术振兴会;
关键词
Multiple myeloma; Bortezomib; Lenalidomide; Thalidomide; Stem cell transplantation; STEM-CELL TRANSPLANTATION; PREDNISONE PLUS THALIDOMIDE; SOUTHWEST-ONCOLOGY-GROUP; HIGH-DOSE DEXAMETHASONE; RANDOMIZED PHASE-III; ELDERLY-PATIENTS; INDUCTION THERAPY; INITIAL THERAPY; BORTEZOMIB INDUCTION; RISK STRATIFICATION;
D O I
10.1007/s12185-013-1294-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The development of novel therapeutic agents over the past decade, including the proteasome inhibitor, bortezomib, and the immunomodulatory drugs, lenalidomide and thalidomide, has resulted in improved outcomes for patients with multiple myeloma. However, there is still considerable controversy as to which regimen should be used as first-line therapy, which patients should be considered for autologous or allogeneic transplantation, and how consolidation or maintenance therapy is used in patients that have a good response to first-line therapy. The present paper will review clinical evidence from previous and ongoing studies to explore issues related to these questions.
引用
收藏
页码:333 / 344
页数:12
相关论文
共 50 条
  • [41] Immunologic approaches for the treatment of multiple myeloma
    Rasche, Leo
    Weinhold, Niels
    Morgan, Gareth J.
    van Rhee, Frits
    Davies, Faith E.
    CANCER TREATMENT REVIEWS, 2017, 55 : 190 - 199
  • [42] Novel Approaches to the Treatment of Multiple Myeloma
    Maples, Kathryn T.
    Scott, Sara A.
    Lonial, Sagar
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (05) : 247 - 256
  • [43] Multiple myeloma: Clinical diagnosis and prospect of treatment. Recommendations of the International Myeloma Working Group (IMWG)
    Manier, S.
    Leleu, X.
    IMMUNO-ANALYSE & BIOLOGIE SPECIALISEE, 2011, 26 (03): : 125 - 136
  • [44] The pharmacologic management of multiple myeloma in older adults
    Dempsey, Jessica L.
    Johns, Andrew
    Rosko, Ashley E.
    Lazarus, Hillard M.
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (07) : 887 - 902
  • [45] Management of treatment-related adverse events in patients with multiple myeloma
    Mateos, Maria-Victoria
    CANCER TREATMENT REVIEWS, 2010, 36 : S24 - S32
  • [46] Clinical treatment of newly diagnosed multiple myeloma
    Cejalvo, Maria J.
    de la Rubia, Javier
    EXPERT REVIEW OF HEMATOLOGY, 2015, 8 (05) : 595 - 611
  • [47] New proteasome inhibitors in the treatment of multiple myeloma
    de Moraes Hungria, Vania Tietsche
    Crusoe, Edvan de Queiroz
    Bittencourt, Rosane Isabel
    Maiolino, Angelo
    Pessoa Magalhaes, Roberto Jose
    Sobrinho, Jairo do Nascimento
    Pinto, Jorge Vaz
    Fortes, Ricardo Coutinho
    Moreira, Eloisa de Sa
    Tanaka, Paula Yurie
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2019, 41 (01) : 76 - 83
  • [48] New developments in the treatment of patients with multiple myeloma
    Minnema, M. C.
    van der Spek, E.
    van de Donk, N. W. C. J.
    Lokhorst, H. M.
    NETHERLANDS JOURNAL OF MEDICINE, 2010, 68 (01) : 24 - 32
  • [49] Advances in the treatment of extramedullary disease in multiple myeloma
    Li, Yating
    Sun, Zhengxu
    Qu, Xiaoyan
    TRANSLATIONAL ONCOLOGY, 2022, 22
  • [50] Current therapeutic strategies for multiple myeloma
    Torimoto, Yoshihiro
    Shindo, Motohiro
    Ikuta, Katsuya
    Kohgo, Yutaka
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2015, 20 (03) : 423 - 430